IN8bio(INAB) - 2024 Q4 - Annual Results

Exhibit 99.1 IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights NEW YORK, March 13, 2025 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. William Ho, Chief Executive Officer and co-founder of IN8bio, commented, "In 2024, IN8bio made significant progress advancing its ...